SINTX Technologies Strengthens IP Portfolio with New U.S. Patent Notice of Allowance Covering Antipathogenic Fabrics

Stock Information for Matinas Biopharma Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Matinas Biopharma Holdings Inc.

SINTX Technologies to Participate in Sidoti & Company Investor Conference
SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride-PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants
SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies
SINTX Technologies Announces Launch of OsseoSculpt(TM) an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System
SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System
UPDATE: SINTX Strengthens Infection-Prevention Portfolio with Newly Allowed U.S. Patent Covering $30 Billion Antipathogenic Addressable Market
SINTX Technologies to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025
SINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross Proceeds

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.